Harm reduction or enforcement: how do the two approaches to the opioid crisis differ?

Public responses to the opioid crisis fall roughly into two camps, and the argument is about which should come first. Enforcement approaches concentrate on the more conventional goals of reducing the supply of drugs and the demand for them. Harm reduction is a range of practices and public health policies designed to lessen the negative social and physical consequences of risky behaviours, both legal and illegal, without requiring abstinence first. For recreational drug use it is put forward as a perspective alongside the more conventional approaches of demand and supply reduction.

In practice, harm reduction has included needle-exchange programmes, which reduce the likelihood of people sharing syringes, and naloxone distribution: many reviews of the research support naloxone-based interventions for reducing overdose deaths where it is available at the time. Another example is the supervised injection site, also called a drug consumption room: a space where people who use drugs are given sterile equipment and can use illicit drugs under the supervision of trained staff. The first opened in Bern, Switzerland, in 1986. In 2022 there were over 100 consumption rooms around the world, though the first government-authorized sites in the US began operating in New York City only in November 2021.

The two sides disagree about what these measures do. Proponents say supervised sites save lives and connect people who use drugs to services, while opponents believe they promote drug use and attract crime to the surrounding community. Critics of harm reduction more generally, such as the Drug Free America Foundation, say it may create the perception that illicit drug use can be safe, and so increase it. Supporters point out that there have been no recorded deaths at any legal supervised injection site.

The evidence is mixed in places. Researchers Rehm and Fischer said that interpretation is limited by weak designs in many evaluations, often lacking adequate control groups. A March 2025 study in British Columbia found that neither safer supply nor decriminalization appeared to mitigate the opioid crisis, and both were associated with an increase in opioid overdose hospitalizations. Neither side owns all the evidence.